OLEMA PHARMACEUTICALS, INC. Lease, Cost
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Lease, Cost of $420.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. lease, cost for the quarter ending 2026-06-30 was $420.00K, a 10.82% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. lease, cost for the quarter ending 2026-03-31 was $409.00K, a 7.35% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. lease, cost for the quarter ending 2025-12-31 was $366.00K, a 4.44% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. lease, cost for the quarter ending 2025-09-30 was $400.00K, a 1.23% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. lease, cost for fiscal 2025 was $1.52M, a 0.46% decline from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. lease, cost for fiscal 2024 was $1.53M, a 4.31% decline from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. lease, cost for fiscal 2023 was $1.60M, a 0.19% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. lease, cost for fiscal 2022 was $1.60M, a 14.14% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $420.00K 10-Q · filed 2026-08-10 | $827.00K 10-Q · filed 2026-08-10 | $1.20M derived: sum of 3 quarters · filed 2026-08-10 | $1.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $409.00K 10-Q · filed 2026-05-12 | $775.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.18M derived: sum of 3 quarters · filed 2026-05-12 | $1.55M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $366.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $766.00K derived: sum of 2 quarters · filed 2026-03-16 | $1.15M derived: sum of 3 quarters · filed 2026-08-10 | $1.52M 10-K · filed 2026-03-16 |
| 2025-09-30 | $400.00K 10-Q · filed 2025-11-10 | $779.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.16M 10-Q · filed 2025-11-10 | $1.54M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $379.00K 10-Q · filed 2026-08-10 | $759.00K 10-Q · filed 2026-08-10 | $1.14M derived: sum of 3 quarters · filed 2026-08-10 | $1.55M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $381.00K 10-Q · filed 2026-05-12 | $764.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.17M derived: sum of 3 quarters · filed 2026-05-12 | $1.54M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $788.00K derived: sum of 2 quarters · filed 2026-03-16 | $1.16M derived: sum of 3 quarters · filed 2026-03-16 | $1.53M 10-K · filed 2026-03-16 |
| 2024-09-30 | $405.00K 10-Q · filed 2025-11-10 | $772.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.15M 10-Q · filed 2025-11-10 | $1.55M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $367.00K 10-Q · filed 2025-08-11 | $744.00K 10-Q · filed 2025-08-11 | $1.15M derived: sum of 3 quarters · filed 2025-08-11 | $1.57M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $377.00K 10-Q · filed 2025-05-13 | $779.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.20M derived: sum of 3 quarters · filed 2025-05-13 | $1.59M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $822.00K derived: sum of 2 quarters · filed 2025-03-18 | $1.21M derived: sum of 3 quarters · filed 2025-03-18 | $1.60M 10-K · filed 2025-03-18 |
| 2023-09-30 | $420.00K 10-Q · filed 2024-11-12 | $809.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.20M 10-Q · filed 2024-11-12 | $1.60M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $389.00K 10-Q · filed 2024-08-06 | $779.00K 10-Q · filed 2024-08-06 | $1.18M derived: sum of 3 quarters · filed 2024-08-06 | $1.59M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $390.00K 10-Q · filed 2024-05-08 | $790.00K derived: sum of 2 quarters · filed 2024-05-08 | $1.20M derived: sum of 3 quarters · filed 2024-05-08 | $1.60M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $811.00K derived: sum of 2 quarters · filed 2024-03-11 | $1.21M derived: sum of 3 quarters · filed 2024-03-11 | $1.60M 10-K · filed 2024-03-11 |
| 2022-09-30 | $411.00K 10-Q · filed 2022-11-08 | $806.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.20M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $395.00K 10-Q · filed 2022-08-09 | $787.00K 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $392.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $1.40M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |